Perioperative management of biologic disease-modifying antirheumatic drugs in patients with inflammatory rheumatic diseases undergoing total joint arthroplasty: A nationwide population-based cohort study from Taiwan
Main finding · SSIResult — go to the resultOdds ratio 1.31Authors' conclusion
Perioperative bDMARD continuation was not associated with a significantly increased risk of SSI or wound complications but substantially reduced disease flares.
Study context
- Population
- Inflammatory rheumatic disease (IRD) patients undergoing primary total joint arthroplasty (TJA), Taiwan National Health Insurance Research Database (NHIRD) 2004–2020
- Participants
- 1,254 propensity-matched IRD patients
- Exposure
- Perioperative bDMARD continuation vs withholding
- Continuationn = 623
- Withholdingn = 631reference
- Outcome
- Primary outcomes: Surgical site infection (SSI), delayed wound healing and disease flares
- Follow-up
- Within 30 days
Methodological detailsnationwide population-based, propensity score-matched
- Nationwide population-based
- Propensity score-matched
Main finding
SSI
Odds ratio
1.31
P = 0.39
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Primary outcome: delayed wound healing · within 30 days
OR 2.02 · P = 0.43
Primary outcome: disease flares · within 30 days
OR 0.13 · P = 0.03
Healthcare costs
- Lower in the continuation group
Original publication
Perioperative management of biologic disease-modifying antirheumatic drugs in patients with inflammatory rheumatic diseases undergoing total joint arthroplasty: A nationwide population-based cohort study from Taiwan. Semin Arthritis Rheum. Published 3 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →